Summit Therapeutics SMMT Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Summit Therapeutics (SMMT) reported proceeds from exercises of stock options and other stock issuances of $3.8M in Q1 2026.
- How has Summit Therapeutics's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Summit Therapeutics's proceeds from exercises of stock options and other stock issuances increased by 88.1% year-over-year, from $2.02M to $3.8M.
- What is the long-term trend for Summit Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2022 to 2025), Summit Therapeutics's proceeds from exercises of stock options and other stock issuances has grown at a 142.0% compound annual growth rate (CAGR), from $399K to $5.65M.